Voxalatamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.

**Synonyms:** - Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081 - JNJ 63898081 - JNJ-63898081 - JNJ-8081 - JNJ63898081 - VOXALATAMAB